These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 18729777)
41. Protection of chickens against H5N1 highly pathogenic avian influenza virus infection by live vaccination with infectious laryngotracheitis virus recombinants expressing H5 hemagglutinin and N1 neuraminidase. Pavlova SP; Veits J; Keil GM; Mettenleiter TC; Fuchs W Vaccine; 2009 Jan; 27(5):773-85. PubMed ID: 19041677 [TBL] [Abstract][Full Text] [Related]
42. Debate on annual influenza vaccination in healthcare workers for the same subtype under the vaccine shortage. Song JY; Ha SH; Kee SY; Jeong HW; Cheong HJ; Kim WJ J Clin Virol; 2007 Feb; 38(2):149-52. PubMed ID: 17196876 [TBL] [Abstract][Full Text] [Related]
43. Development of Eurasian H7N7/PR8 high growth reassortant virus for clinical evaluation as an inactivated pandemic influenza vaccine. Jadhao SJ; Achenbach J; Swayne DE; Donis R; Cox N; Matsuoka Y Vaccine; 2008 Mar; 26(14):1742-50. PubMed ID: 18336962 [TBL] [Abstract][Full Text] [Related]
44. Changing perspective on immunization against influenza. Johansson BE; Brett IC Vaccine; 2007 Apr; 25(16):3062-5. PubMed ID: 17276554 [TBL] [Abstract][Full Text] [Related]
45. [Influenza season 2007/'08 in the Netherlands: antigenic variation, oseltamivir resistance and vaccine composition for the 2008/'09 season]. Rimmelzwaan GF; de Jong JC; Donker GA; Meijer A; Fouchier RA; Osterhaus AD Ned Tijdschr Geneeskd; 2008 Sep; 152(39):2138-44. PubMed ID: 18856032 [TBL] [Abstract][Full Text] [Related]
46. Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007. Skowronski DM; De Serres G; Dickinson J; Petric M; Mak A; Fonseca K; Kwindt TL; Chan T; Bastien N; Charest H; Li Y J Infect Dis; 2009 Jan; 199(2):168-79. PubMed ID: 19086914 [TBL] [Abstract][Full Text] [Related]
48. Immunology. Flu antibodies stir new hope for treatment, vaccine. Leslie M Science; 2009 Feb; 323(5918):1160. PubMed ID: 19251602 [No Abstract] [Full Text] [Related]
49. Haemagglutination-inhibiting antibody to influenza virus. de Jong JC; Palache AM; Beyer WE; Rimmelzwaan GF; Boon AC; Osterhaus AD Dev Biol (Basel); 2003; 115():63-73. PubMed ID: 15088777 [TBL] [Abstract][Full Text] [Related]
50. Impact of influenza vaccine formulation with a detailed analysis of the cytokine response. Szyszko E; Brokstad K; Cox RJ; Hovden AO; Madhun A; Haaheim LR Scand J Immunol; 2006 Nov; 64(5):467-75. PubMed ID: 17032238 [TBL] [Abstract][Full Text] [Related]
51. Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant? Skowronski DM; Tweed SA; De Serres G J Infect Dis; 2008 Feb; 197(4):490-502. PubMed ID: 18275271 [TBL] [Abstract][Full Text] [Related]
52. Improved antibody responses in infants less than 1 year old using intradermal influenza vaccination. Sugimura T; Ito Y; Tananari Y; Ozaki Y; Maeno Y; Yamaoka T; Kudo Y Vaccine; 2008 May; 26(22):2700-5. PubMed ID: 18436353 [TBL] [Abstract][Full Text] [Related]
53. Learning from the 2009 H1N1 pandemic: prospects for more broadly effective influenza vaccines. Settembre EC; Dormitzer PR; Rappuoli R J Mol Cell Biol; 2011 Jun; 3(3):144-6. PubMed ID: 21430014 [TBL] [Abstract][Full Text] [Related]
54. Enumeration of haemagglutinin-specific CD8+ T cells after influenza vaccination using MHC class I peptide tetramers. Kosor Krnic E; Gagro A; Drazenovic V; Kuzman I; Jeren T; Cecuk-Jelicic E; Kerhin-Brkljacic V; Gjenero-Margan I; Kaic B; Rakusic S; Sabioncello A; Markotic A; Rabatic S; Mlinaric-Galinovic G; Dekaris D Scand J Immunol; 2008 Jan; 67(1):86-94. PubMed ID: 18052968 [TBL] [Abstract][Full Text] [Related]
55. Trends in development of the influenza vaccine with broader cross-protection. Stropkovská A; Janulíková J; Varecková E Acta Virol; 2010; 54(1):7-19. PubMed ID: 20201609 [TBL] [Abstract][Full Text] [Related]
56. Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects. Treanor J; Nolan C; O'Brien D; Burt D; Lowell G; Linden J; Fries L Vaccine; 2006 Jan; 24(3):254-62. PubMed ID: 16129526 [TBL] [Abstract][Full Text] [Related]
57. Sindbis virus vectors elicit hemagglutinin-specific humoral and cellular immune responses and offer a dose-sparing strategy for vaccination. Miller A; Center RJ; Stambas J; Deliyannis G; Doherty PC; Howard JL; Turner SJ; Purcell DF Vaccine; 2008 Oct; 26(44):5641-8. PubMed ID: 18761047 [TBL] [Abstract][Full Text] [Related]